基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抗体 一抗 临床级别 CD20(抗体) Human CD20蛋白
  • 重组人CD20 / MS4A1蛋白, His Tag
  • 重组人CD20 / MS4A1蛋白, His Tag
  • 重组人CD20 / MS4A1蛋白, His Tag

1/3

重组人CD20 / MS4A1蛋白, His Tag

CD20
询价 100ug 起订
500ug 起订
1000ug 起订
北京 更新日期:2025-12-30

北京百普赛斯生物科技股份有限公司

VIP3年
联系人:赵先生
手机:13121935750 拨打
邮箱:jiaxin.zhao@acrobiosystems.com

产品详情:

中文名称:
Human CD20蛋白
英文名称:
CD20
品牌:
百普赛斯
产地:
北京
保存条件:
-20°C to -70°C
纯度规格:
99.9%
产品类别:
重组蛋白
货号:
CD20
用途范围:
科研
规格:
100ug
是否进口:

FITC-Labeled Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc, SPR verified) 

分子别名(Synonym

MS4A1,CD20,MS4A-1

表达区间及表达系统(Source

FITC-Labeled Human CD20 Full Length Protein, His Tag (CD0-HF2H5) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

Predicted N-terminus: Met 1

蛋白结构(Molecular Characterization

1.jpg

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 35.2 kDa. The protein migrates as 26 kDa, 40 kDa and 70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution.

2.jpg

The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein(MSP1D1) upon removal of the detergent.

偶联(Conjugate

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

标记(Labeling

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

内毒素(Endotoxin

Less than 1.0 EU per μg by the LAL method.

纯度(Purity

>85% as determined by SDS-PAGE.

制剂(Formulation

Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

运输(Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

The product MUST be stored at -70°C or lower upon receipt;

-70°C for 3 months under sterile conditions.

3.jpg

4.jpg

背景(Background

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

CD20;CD20蛋白;CD20重组蛋白;ACRO;百普赛斯;

公司简介

百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。

成立日期 (16年)
注册资本 8000万人民币
员工人数 500人以上
年营业额 ¥ 1亿以上
经营模式 工厂,试剂
主营行业 医药中间体,原料药,激素类,氨基糖苷类,中枢神经系统用药

Human CD20蛋白相关厂家报价 更多

内容声明
拨打电话 立即询价